Press Releases Johnson & Johnson NEO Exchange

Equities

JNJ

CA47817E1034

End-of-day quote NEO Exchange Other stock markets 06:00:00 2024-06-05 pm EDT			5-day change	1st Jan Change
19.63 ^CAD	+0.20%		+0.82%	-7.19%

05:15pm	J&J-backed Rapport Therapeutics shares debut nearly 6% higher	RE
03:06pm	J&J: FDA approves VELYS for knee arthroplasty	CF

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Johnson & Johnson : DePuy Synthes Receives 510(k) FDA Clearance of the VELYS™ Robotic-Assisted Solution for Use in Unicompartmental Knee Arthroplasty Procedures	09:58am	PU
Johnson & Johnson Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Pediatric Indication for HIV-1 Therapy PREZCOBIX	Jun. 05	AQ
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results	Jun. 04	BU
Johnson & Johnson : showcases innovation and leadership in rheumatology at EULAR 2024 Congress	Jun. 04	PU
Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors	Jun. 04	AQ
Johnson & Johnson Completes Acquisition of Shockwave Medical	Jun. 03	AQ
Johnson & Johnson - First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration	Jun. 03	AQ
Johnson & Johnson Executive Vice President, William N. Hait, M.D., Ph.D., to Retire, Effective September 2024	May. 31	AQ
Johnson & Johnson Completes Acquisition of Shockwave Medical	May. 31	BU
Johnson & Johnson : to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC) Press Release	May. 29	PU
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results	May. 29	AQ
Johnson & Johnson : to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC) Transcript	May. 28	PU
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis	May. 28	AQ
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis	May. 28	BU
Johnson & Johnson: Meet a nurse who leads clinical trials to find innovative cancer therapies	May. 24	AQ
Johnson & Johnson : advances leadership in oncology innovation with more than 75 clinical study and real-world presentations at ASCO and EHA	May. 24	PU
Proposed Class Action Filed by Six Law Firms Alleging Series of Fraudulent Transfers by Johnson & Johnson in Talc Litigation	May. 22	BU
Engitix Announces Appointment of Matthew Edwards Ph.D., as SVP Discovery and Emma Huang Ph.D., as VP Data Sciences	May. 22	AQ
TREMFYA (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major secondary endpoints, including highly statistically significant rates of endoscopic remission	May. 21	AQ
Novel biologic could offer ulcerative colitis symptomatic remission	May. 21	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm EST